|Day Low/High||42.78 / 45.99|
|52 Wk Low/High||37.59 / 55.51|
The pharma company has been increasing the price of the epinephrine injector since 2007, so why are people finally taking notice?
U.S. stock losses grew heavier Wednesday as the afternoon wore-on with a selloff in crude oil and health care stocks leading Wall Street into the red.
Shares of the world's second largest generic pharma company fell nearly 5% after U.S. politicians target company for price gouging.
A selloff in crude oil and health care stocks led Wall Street into the red on Wednesday.
The Nasdaq Biotechnology Index fell 3.5% heading into Wednesday's close, with the loss triggered by a statement from Clinton's presidential campaign blasting Mylan for 'outrageous' pricing of the EpiPen.
Mylan (MYL) stock has slumped this week as the pharmaceutical company faces public criticism over the high price of its EpiPens.
BTIG managing director Tim Chiang joined CNBC's 'Power Lunch' Tuesday afternoon to explain the 'buy' rating he has on Mylan (MYL) shares.
Citigroup analysts say recent public scrutiny over Mylan's (MYL) EpiPen won't affect its earnings, but could 'weigh on the stock's multiple' in the near term.
Senators Grassley, Blumenthal and Klobuchar demand Mylan reduce the price of its dominant treatment for life-threatening allergies.
Iowa Senator Chuck Grassley has officially requested Myaln (MYL) explain its price increases for the EpiPen.
Prices of Mylan's (MYL) EpiPen have reportedly increased 450% since 2004.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ELP, FCB, FGBI, HMC, IRT, JACK, JCP, MYL, NMIH, OBAS, SEED Downgrades: ATNI, CXW, PFIN, RIC, WABC Initiations: None Read on to get TheStreet Quant Ratings' detailed report:
The Pittsburgh-based pharmaceutical company has been steadily jacking up the price of the auto injectors since 2010 to bolster revenues.
Despite cutting its full year guidance, the company continues to have a lot of potential upside.
Perrigo might have been in more of a decline than the market realized when it turned down Mylan's $26 billion offer for the company last year, says Jim Cramer.
Stock futures are rising on Wednesday as investors consider earnings from Disney and retailers.
Mylan (MYL) stock was trading lower after-hours on Tuesday after reporting financial results for the 2016 second quarter.
The stock should break above the resistance line on its way to its December high of around $55, if it beats earnings expectations late Tuesday.
Tennis icon Billie Jean King co-founded World Team Tennis (WTT) in 1974 and the organization's intent resonates more today than ever before with tennis fans.
The stock is breaking out of consolidation patterns on multiple timeframes.
Mylan Has Declared the Offer Unconditional, with Settlement Expected to Occur on Aug. 5, 2016